Tazimax IM/IV Injection

Introduction

Ceftazidime pentahydrate is a broad-spectrum cephalosporin antibiotic used to treat a variety of bacterial infections. It is effective against many Gram-negative bacteria and some Gram-positive bacteria, making it a valuable option in treating serious infections.

Uses

Ceftazidime pentahydrate is commonly used for:

Severe infections, including those of the respiratory tract, urinary tract, skin, and bones.
Intra-abdominal infections, including peritonitis and intra-abdominal abscesses.
Neutropenic fever, often in patients with cancer undergoing chemotherapy.
Infections caused by Pseudomonas aeruginosa and other Gram-negative bacteria.

It is typically used when other antibiotics are ineffective or when treating infections caused by resistant organisms.

Brand Name	Tazimax
Type	IM/IV Injection
Weight	1 gm/vial
Generic	Ceftazidime Pentahydrate
Manufacturer	Eskayef Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Ceftazidime pentahydrate works by inhibiting bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs) on the bacterial cell wall, disrupting cell wall synthesis and leading to bacterial cell death. This action is effective against a wide range of Gram-negative and some Gram-positive bacteria.

How Long Does It Take to Work?

The effects of Ceftazidime pentahydrate are usually observed within 48 to 72 hours of starting treatment. The exact time may vary depending on the severity of the infection, the bacterial strain, and the patient's overall health condition.

Absorption

Ceftazidime pentahydrate is administered intravenously or intramuscularly, bypassing the gastrointestinal tract. This method ensures immediate and complete absorption into the bloodstream.

Route of Elimination

The drug is primarily eliminated through the kidneys, with about 80% of the dose excreted unchanged in the urine. A small amount is eliminated through bile in the feces.

Dosage

The usual dosage of Ceftazidime pentahydrate is:

For adults: 1 to 2 grams every 8 to 12 hours, depending on the severity of the infection and the patient's renal function.
For pediatric patients: Dosage is adjusted based on weight and specific infection.

Dosage may be adjusted based on the type of infection, the severity of the condition, and the patient's renal function.

Administration

Ceftazidime pentahydrate is administered via intravenous infusion or intramuscular injection. The route and frequency depend on the infection being treated and the patient's condition. Follow healthcare provider instructions for proper administration.

Side Effects

Common side effects include:

Diarrhea or gastrointestinal discomfort.
Rash or allergic reactions.
Pain at the injection site.

Serious side effects may include severe allergic reactions, liver dysfunction, or blood disorders. Report any severe side effects to a healthcare provider immediately.

Toxicity

Toxicity from Ceftazidime pentahydrate may result from excessive dosing or prolonged use, leading to:

Severe gastrointestinal symptoms such as nausea, vomiting, and diarrhea.
Potential renal or hepatic dysfunction.
CNS effects like confusion or seizures in extreme cases.

In cases of toxicity, discontinuation of the drug and supportive care are usually required.

Precautions

Precautions include:

Regular monitoring of renal and hepatic function during treatment.
Use cautiously in patients with a history of allergic reactions to cephalosporins or penicillins.
Potential interactions with other drugs that affect renal or hepatic function.

Regular monitoring and appropriate dose adjustments are essential to ensure safety.

Interaction

Ceftazidime pentahydrate may interact with:

Probenecid, which can inhibit the renal excretion of Ceftazidime, leading to higher blood levels.
Other antibiotics, which may affect the efficacy of Ceftazidime.

Inform your healthcare provider of all medications and supplements you are taking to manage potential interactions effectively.

Disease Interaction

Considerations for patients with:

Renal impairment, as dosage adjustments may be needed to prevent accumulation and toxicity.
Hepatic dysfunction, as Ceftazidime is metabolized in the liver and may require dose adjustments.

Regular assessment of the patient's condition is necessary to tailor the treatment appropriately.

Drug Interaction

Drug interactions include:

Probenecid, which can increase Ceftazidime levels in the blood by reducing renal excretion.
Other drugs affecting liver enzymes, potentially altering Ceftazidime metabolism.

Monitor for potential interactions and adjust treatment as necessary.

Food Interactions

Food interactions are minimal since Ceftazidime pentahydrate is administered parenterally. However, follow any additional dietary instructions provided by your healthcare provider.

Pregnancy Use

Ceftazidime pentahydrate is categorized as pregnancy category B, indicating that it is generally considered safe for use during pregnancy. It should only be used if clearly needed, with careful assessment of risks versus benefits.

Lactation Use

Ceftazidime pentahydrate is excreted in breast milk in small amounts. It is generally considered safe during lactation, but it is important to consult a healthcare provider to discuss potential effects on the infant and determine appropriateness of use.

Acute Overdose

Acute overdose of Ceftazidime pentahydrate can cause:

Severe gastrointestinal symptoms such as nausea, vomiting, and diarrhea.
Potential renal or hepatic impairment.
CNS effects such as confusion or seizures in extreme cases.

Seek immediate medical attention if an overdose is suspected. Treatment typically involves supportive care and symptomatic management.

Contraindication

Ceftazidime pentahydrate is contraindicated in:

Patients with known hypersensitivity to cephalosporins or other beta-lactam antibiotics.
Patients with severe renal impairment without proper monitoring.

Ensure a thorough evaluation before initiating treatment to identify any contraindications.

Use Direction

Adhere to the prescribed dosage and administration guidelines provided by your healthcare provider. Do not adjust the dose or discontinue the medication without professional guidance. Complete the full course of treatment to ensure effectiveness.

Storage Conditions

Store Ceftazidime pentahydrate at room temperature, away from light, moisture, and heat. Keep the medication in its original container and out of reach of children. Follow any specific storage instructions from the manufacturer or healthcare provider.

Volume of Distribution

The volume of distribution for Ceftazidime pentahydrate is approximately 20 liters, reflecting its distribution throughout the body fluids and tissues. This helps in achieving effective concentrations in the areas of infection.

Half Life

The half-life of Ceftazidime pentahydrate is approximately 1.5 to 2.5 hours. Due to this relatively short half-life, it is typically administered multiple times per day to maintain therapeutic drug levels.

Clearance

Ceftazidime pentahydrate is primarily cleared by the kidneys. The clearance rate is influenced by renal function, so dosage adjustments may be necessary for patients with renal impairment to avoid accumulation and toxicity.

See in details version Tazimax IM/IV Injection 1 gm/vial also Tazimax IM/IV Injection 1 gm/vial in bangla